An interventional study of Person-centred team-based approach in Chronic Pain, Chronic Pain Management and Primary Care, sponsored by Uppsala County Council, Sweden. Recruiting at 4 sites in Sweden. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-30.
Sponsored by Uppsala County Council, Sweden · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Chronic Pain with a site in Sweden — 30 open to participants now, 37 under way, none of them phase 3. Chronic Pain · Sweden.
Among the 88 studies in Chronic Pain with a site in Sweden, this one is the 27th largest by planned enrollment of the 65 interventional ones that give a count, is one of 9 that started in 2025, is one of 61 with no phase, reaches primary completion later than 28 of the 36 other live ones, and was the 72nd registered.
3,228 studies on the registry are indexed under Chronic Pain; 728 are open to participants now.
Browse Chronic Pain studies →30 of the 88 studies in Chronic Pain with a site in Sweden are open now. Recruiting first, the newest first:
Skane University Hospital · Sites in Sweden
Ages 15–24
Karolinska Institutet · Sites in Sweden
Ages 18+
Skane University Hospital · Sites in Sweden
Ages 18–65
Catholic University of the Sacred Heart · Sites in Sweden, Italy
Ages 18+
Lund University · Sites in Sweden
Ages 18+
A study can be open while its sites in Sweden have not opened yet or have stopped. Only those recruiting at a site in Sweden →
Of the 486 Chronic Pain studies recruiting now, 239 (49%) set no upper age limit and 173 (36%) stop at 75 or younger; 43 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 1 · Phase 4 1
First in 2004; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 110 is above the median of 60 across 2,388 interventional studies indexed under Chronic Pain.
Median enrollment 80 across the 65 interventional studies, 144 across the 23 observational. Of the 44 that completed or were terminated, 3 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 88 have an industry lead sponsor. The 10 most frequent:
Uppsala County Council, Sweden is the lead sponsor of 7 studies on the registry; 3 are open to participants now.
Uppsala County Council, Sweden has 1 study filed under Chronic Pain — fewer than ten, so there is no comparison to draw.
11 of the studies in Chronic Pain with a site in Sweden that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06410963Örebro University, SwedenReActivate: Physiotherapist Led Intervention for A Adolescents and Young Adults With Musculoskelatal Pain | 2026-11-30 |
| NCT06981312Region StockholmInternet-Delivered Psychological Treatments for Chronic Pain in Adolescents: ACT and Pain Education. | 2026-12 |
| NCT06084390Vastra Gotaland RegionInterdisciplinary Rehabilitation for Chronic Pain in Primary Healthcare | 2026-12-31 |
| NCT06981611Karlstad UniversityVulvodynia Intervention: the Effect of Multimodal Treatment for Provoked Vulvodynia | 2026-12-31 |
| NCT07092332Region Örebro CountyYoung Vulvodynia: Effect and Efficacy of Multimodal Treatment. | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 88 studies in Chronic Pain with a site in Sweden, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to reduce inappropriate long term opioid treatment (LTOT) and to optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centred and team-based approach. The main question it aims to answer is:
What are the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care?
Researchers will compare a new person-centred and team-based approach to usual care to see if pain interference is lower.
Participants will receive a person-centred team-based treatment consisting of:
The evidence for prescribing opioids to patients suffering from chronic non-cancer pain is weak, and using opioids in these circumstances is questionable. Swedish primary health care is responsible for about one-third of all first-time opioid prescriptions and has the highest rate of prescription renewals for opioids. The decision for long-term opioid therapy (LTOT) should rest on an accurate pain analysis and should result in an individualized assessment where the risks of LTOT are set against the impact on quality of life that living with long-term pain entails. Multi-professional interventions and a person-centered approach are recommended for chronic non-cancer pain. Although pharmacists in primary health care have been established internationally with successful examples related to LTOT, their role in Swedish primary care and the management of chronic non-cancer pain remains to be studied. Currently, it is unclear which interventions are effective in reducing inappropriate LTOT and which alternative interventions are suitable for patients who are currently receiving LTOT. The involvement of a care manager in the patient´s care has shown promising results regarding quality of care for other long-term conditions, for example depresssion. In Region Uppsala, clinical pharmacists havte recently been employed in primary health care, but it is unclear what their tasks and responsibilities are and how to best make use of their competence. It is therefore relevant and justified to investigate a new person-centered team-based approach including care manager and pharmacist to optimize the management of pain in patients with chronic non-cancer pain in Swedish primary care. This project aims to reduce inappropriate LTOT and optimize pain management in patients with LTOT for chronic non-cancer pain in primary care through a new person-centered and team-based approach.
Primary objective:
To investigate the effects of a new person-centred and team-based approach on pain interference in patients with LTOT for chronic non-cancer pain in primary care
Trial design and setting:
This study is a controlled before-and-after study that has been designed, and will be reported, according to the CONSORT guidelines. Participation will be during 52 weeks (12 months).
This study will be conducted at eight healthcare centres in Region Uppsala. At four of the healthcare centres, a new person-centred team-based treatment model including pharmacists (intervention) will be implemented. Prerequisites for these healthcare centres are the accessibility of at least one person of each healthcare profession: pharmacist, general practitioner (GP), psychologist (or social worker) and physiotherapist, where one of these (or a rehabilitation coordinator or a nurse) takes the role of care manager. Healthcare personnel will receive special training in managing patients with chronic pain before the study. In addition, four control healthcare centres without a pharmacist will be matched with the intervention healthcare centres according to geographic area (urban, suburban, rural), socioeconomical setting and the size of the centres (number of listed patients). No specific efforts of implementation will be made in these control centres.
Prior to the full trial, a feasibility study will be conducted at one intervention centre and one control centre with 12 weeks follow-up per participant.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in the control healthcare centres will receive usual care. This may include appointments and treatment by a general practitioner, nurse, physiotherapist and/or psychologist. No pharmacist will be working at the healthcare centre. However, Uppsala County Council does provide centralized medication review services to all primary healthcare centres in Region Uppsala. Any healthcare professional may request a medication review by a pharmacist on a work-from-home basis as part of usual care.
Phase 1 (investigation and assessment, week 1-3): * A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist. * A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms. * A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities. * A visit to a psychologist for diagnostics and treatments regarding psychological and social factors. * A visit to a care manager Phase 2 (treatment plan, week 3-4): \- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made. Phase 3 (treatment and follow-up, week 4-24): * Implementation of the individualized rehabilitation plan. * Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager. * A second team consultation half-way
Behavioral: Person-centred team-based approach
Phase 1 (investigation and assessment, week 1-3): * A medication review focusing on pain, sleep and depression/anxiety disorders by a pharmacist. * A thorough pain analysis by a GP according to existing guidelines including duration of pain, pain localization and pain mechanisms. * A visit to a physiotherapist for evaluation and assessment of possible treatment regarding physical exercise/physical activities. * A visit to a psychologist for diagnostics and treatments regarding psychological and social factors. * A visit to a care manager Phase 2 (treatment plan, week 3-4): \- A team consultation with all healthcare personnel involved in Phase 1 including the patient where an individualized rehabilitation plan is made. Phase 3 (treatment and follow-up, week 4-24): * Implementation of the individualized rehabilitation plan. * Frequent follow-up contacts (1 per 1-3 weeks) by phone with an established contact person, i.e. care manager. * A second team consultation half-way
Pain interference
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.
Time frame: The primary outcome measure will be the difference in mean pain interference after 6 months.
Pain intensity
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 3-8. Scale: 0-10. Higher score is worse
Time frame: After 3, 6 and 12 months
Symptoms of depression
Measured with the Patient Health Questionnaire-9 (PHQ-9). Scale: 0-27. Higher score is worse
Time frame: After 3, 6 and 12 months
Symptoms of anxiety
Measured with the General Anxiety disorder-7 (GAD-7). Scale: 0-27. Higher score is worse
Time frame: After 3, 6 and 12 months
Patient satisfaction
Measured with the Patients´ Global impression of Change (PGIC). Scale: 0-6. Higher score is worse
Time frame: After 3, 6 and 12 months
Quality of life according to the 5-level EuroQol 5D
Measured with the 5-level EuroQol 5D (EQ-5D-5L). Scale: 1-5 per dimension. Higher score is worse.
Time frame: After 3, 6 and 12 months
Opioid use
Measured with as morphine equivalents: in mg.
Time frame: After 3, 6 and 12 months
Symptoms of withdrawal
Measured with the Short Opioid Withdrawal Scale (SOWS). Scale: 0-40. Higher score is worse
Time frame: After 3, 6 and 12 months
Pain interference
Measured with the Brief Pain Inventory - Short Form (BPI-SF), question number 9 a-g. Scale: 0-10. Higher score is worse.
Time frame: After 3 and 12 months
Plan to share: Undecided
Started Mar 2025 (actual). Primary completion is estimated for Jun 2028, 39 months after the start.
Of 1,297 non-industry interventional studies with no phase under Chronic Pain, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 39. This study's planned 39 months is above that.
Counting every sponsor, half of 1,380 studies reached it within 20 months; a quarter within 9 and three quarters within 38.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 30, 2026: primary completion Dec 2028 → Jun 2028 and completion Jun 2029 → Dec 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Uppsala County Council, Sweden